Shiv Srivastava, PhD

Dr. Shiv Srivastava is an accomplished cancer researcher, a leader and a mentor who has dedicated four decades of his professional career focused on cancer science for the benefit of patients. Currently, he contributes to the basic science/translational cancer research in an advisory role. He also serves as an Adjunct Professor at the Georgetown University in Washington DC. Dr. Shiv Srivastava was Judd W. Moul Professor at the Uniformed Services University of the Health Sciences (USUHS), where he served as the founding Scientific Director and Co-Director of the Department of Defense-Center for Prostate Disease Research (CPDR)/Prostate Cancer of Excellence for over 25 years. Dr. Srivastava co-led the establishment of the multi-disciplinary basic science and translational research programs in prostate cancer and unique bio- resources at the USUHS, Walter Reed National Military Medical Center (WRNMMC) and Murtha Cancer Center (MCC). His research focuses have been the discovery and translation of prostate cancer driver genes, the development or evaluation of technologies for improving prognosis and treatment of prostate cancer, and the molecular basis of racial disparity in prostate cancer. Shiv earned his PhD from the Indian Institute of Technology (IIT), Delhi, and completed fellowships at the Memorial Sloan-Kettering Cancer Center and the National Cancer Institute. He has co-authored over 210 papers and over 12 patents in the field of cancer molecular biology and translational research. Some of the his landmark research accomplishments include discoveries of common oncogenic alterations (ERG) in prostate cancer and the germline mutations of the TP53 gene in Li-Fraumeni Syndrome. His training/mentoring initiatives have inspired a large cadre of next-generation of bio-medical researchers (250+). He continues to serve the cancer research community as consultant, collaborator, mentor, advisory committee member, and reviewer for leading cancer journals and funding agencies. He remains a strong champion for accelerating research that enhances precision medicine for cancer patients.